Finance

Lists
PTCT:NASDAQ
PTC Therapeutics, Inc.
$63.49
+0.21%
(+0.13) 1D
Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PTCT...
Open
$63.12
High
$63.74
Low
$62.51
Mkt. cap
5.30B
Avg. vol.
1.09M
Volume
30.00
52-wk high
$90.87
52-wk low
$58.80
EPS
-$1.38
Beta
0.52
Shares outstanding
83.54M
No. of employees
991
Open
$63.12
High
$63.74
Low
$62.51
Mkt. cap
5.30B
Avg. vol.
1.09M
Volume
30.00
52-wk high
$90.87
52-wk low
$58.80
EPS
-$1.38
Beta
0.52
Shares outstanding
83.54M
No. of employees
991
News stories
From web sources and news partners
Profile
PTC Therapeutics, Inc. is an U.S.-based pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapies that alter gene expression via post-transcriptional control mechanisms in orphan diseases. In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorHealth Care
IndustryBiotechnology
Websiteptcbio.com
Analyst ratings
Based on 12 analysts giving stock ratings to PTCT in the past 3 months
Strong buy
Buy
10
Hold
2
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for PTCT in the last 3 months.
Highest
Current $63.49
$137.00 (+115.78%)
Average
$100.00 (+57.51%)
Lowest
$62.00 (-2.35%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Cheng
J.P. Morgan
Buy
Maintained
$92.00
+44.9%
11/05/2026
Eric Joseph
Citi
Buy
Maintained
$109.00
+71.7%
11/02/2026
Eliana Merle
Barclays
Buy
Maintained
$122.00
+92.2%
11/02/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
-
-
10/30/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$137.00
+115.8%
10/29/2026
Joseph Thome
TD Cowen
Buy
Maintained
$95.00
+49.6%
10/30/2026
Joon Lee
UBS
Buy
Maintained
$90.00
+41.8%
10/30/2026
Benjamin Burnett
Wells Fargo
Buy
Maintained
$112.00
+76.4%
10/30/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$77.00
+21.3%
10/29/2026
Tiago Fauth
Raymond James
Buy
Maintained
$106.00
+67%
10/20/2026
Alex Nackenoff
Truist Financial
Hold
Initiated
$62.00
-2.3%
10/16/2026
Unknown Analyst
Truist Financial
Hold
Initiated
$62.00
-2.3%
10/16/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
$109.00
+71.7%
10/16/2026
Jim Kelly
Leerink Partners
Buy
Upgraded
$98.00
+54.4%
09/14/2026
Basma Radwan
Leerink Partners
Buy
Initiated
$98.00
+54.4%
09/14/2026
Unknown Analyst
Leerink Partners
Buy
Upgraded
$98.00
+54.4%
09/14/2026
Paul Choi
Goldman Sachs
Sell
Maintained
$70.00
+10.3%
07/30/2026
Judah Frommer
Morgan Stanley
Buy
Maintained
$104.00
+63.8%
07/31/2026
Faisal Khurshid
Jefferies
Buy
Upgraded
$85.00
+33.9%
05/27/2026
Geoff Meacham
Citi
Hold
Maintained
$75.00
+18.1%
05/07/2026
Unknown Analyst
Raymond James
Buy
Initiated
$108.00
+70.1%
04/09/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
02/20/2026
Last report
Oct 29, 2026
Fiscal period
Q3 2026
-$0.39 / $0.30
-229.50%miss
Revenue / Est. (USD)
357.81M / 305.01M
+17.31%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
164.68M
272.55M
360.52M
357.81M
Cost of goods sold
140.08M
129.70M
119.07M
129.02M
Cost of revenue
140.08M
129.70M
119.07M
129.02M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
96.87M
86.18M
80.63M
80.08M
Operating expense
106.22M
97.76M
92.47M
92.68M
Total operating expenses
246.30M
227.46M
211.54M
221.69M
Operating income
-81.62M
45.09M
148.98M
136.11M
Other non operating income
-10.81M
-1.00M
35.00K
127.00K
EBT including unusual items
-139.08M
-2.46M
97.54M
-41.09M
EBT excluding unusual items
-150.16M
-3.55M
100.93M
88.07M
Income tax expense
-4.12M
347.00K
14.05M
10.60M
Effective tax rate
2.96%
-14.09%
14.40%
-25.81%
Other operating expenses
-
-
-
-
Net income
-134.96M
-2.81M
83.50M
-51.69M
Net profit margin
-81.96%
-1.03%
23.16%
-14.45%
Earnings per share
-1.80
-0.03
0.92
-0.39
Interest and investment income
5.30M
17.98M
18.12M
20.93M
Interest expense
-57.32M
-67.02M
-66.60M
-67.90M
Net interest expenses
-52.03M
-49.03M
-48.48M
-46.97M
Depreciation and amortization charges
-
-
-
-
EBITDA
-68.72M
60.50M
164.85M
152.93M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps